TAUNS Laboratories, Inc.

Notice of Adoption ofAMED (Japan Agency for Medical Research and Development) Publicly Offered Projects
SHIZUOKA, Japan, November 7, 2023- TAUNS Laboratories, Inc. (Headquarters:
Izunokuni-shi, Shizuoka, Japan; President and CEO: Masaki Nonaka; hereinafter referred toas "TAUNS") announces that its proposals have been adopted by AMED (Japan Agency for
Medical Research and Development) for publicly offered projects as follows.
（１）
Call for Proposals: Research on the Practical Application of Medical Technology forDeveloping and Emerging Countries
Adopted Project Title: Development of an Antigen Test System for Treatment Monitoring ofTuberculosis
Principal Investigator: TAUNSCo-Investigator: The Research Institute of Tuberculosis, Japan Anti-Tuberculosis
Association (Director: Seiya Kato)
Research Description:
According to statistics* from the World Health Organization (WHO), approximately 10.6
million people worldwide are reported to develop tuberculosis (TB) annually, andapproximately 1.6 million people die from the disease. Since the treatment of TB is a longterm process, it is vital to accurately monitor the progress of treatment. However, existing
testing methods have their advantages and disadvantages, and there is no test that is optimalfor treatment monitoring. Our proprietary technology can solve this problem, and we aim todevelop a new antigen testing system that can be widely used in developing and emerging
countries where TB is devastatingly prevalent.
Research and Development Period: August 2023 - March 2026 (planned)*WHO. Global Tuberculosis Report 2022.

（２）
Call for Proposals: Project for Strengthening Advanced R&D and Development Systems in
Medical Devices, etc. (Strengthening Medical Device Development Systems)
Adopted Project Title: Development of a novel and highly sensitive blood coagulation testing
system to prevent the onset of thrombosis that often occurs in large-scale disasters

Principal Investigator：TAUNSCo-Investigators:-Kumamoto University (Kenichi Tsujita, Professor, Department of CardiovascularMedicine, Faculty of Life Sciences; Yuichiro Arima, Associate Professor, International
Research Center for Medical Sciences)-Thrombo Translational Research Lab Inc. (Headquarters: Kumamoto, Japan; President:
Yuichi Kamikubo)

Research Description:
During disasters such as major earthquakes, evacuees are forced to sleep crowded together onthe floor of evacuation shelters or in cars under poor conditions, with very limited drinking
water available to evacuees, which has been reported to cause thrombosis such as Economy
Class Syndrome. When symptoms of suspected thrombosis such as swelling and sluggishnessof the lower limbs are observed in evacuees, an immediate thrombosis test, ultrasonographyneeds to be performed to diagnose thrombosis. However, due to few doctors and technicians
who are required for carrying out the test in evacuation centers, the current testing systemdoes not seem to be sufficient to find out patients with high risk of thrombosis before theonset. The unsolved issue has prompted us to propose to AMED a thrombosis testing systemthat is compact and can be easily operated by anyone. Specifically, we will develop a small andsimple testing system (i.e., point of care testing: POCT) that can detect the initial minuteamounts of thrombin production in the early stages of thrombus formation in blood vessels
based on the state of the art coagulation test the SMAT (Smart Analysis of ThrombinProduction) developed by Thrombo Translational Research Lab Inc.
Research and Development Period: September 2023 - March 2026 (planned)

About TAUNS:TAUNS Laboratories, Inc. is one of the major companies of rapid diagnostic test kits for
infectious diseases in Japan. We manufacture in vitro diagnostic test kits and research
reagents applying various diagnostic technologies for global consumption. In the field of rapid
diagnostic test kits for infectious diseases, which are our main products, we have been widely
known for high-quality products and customer services by hospitals, clinics, research
institutes and biotech start-ups. For over 30 years since the company was established in 1987,
under the corporate philosophy of enriching lives and providing peace of mind, we havestrived to develop and improve our products. As a leading company of rapid diagnostic test
kits in Japan, we continue to advance R&D to meet the needs for clinical tests.

The purpose of this release is to provide our stakeholders with the latest information related to our company.
Although it may contain information on our products and research and development, it is intended to disclose
our management information and is not intended as promotion, advertisement, or medical advice regarding
our products.

For inquiries regarding this press release, please contact:
General Affairs Department, TAUNS Laboratories, Inc.
E-mail: kouhou@tauns.co.jp